Companies › Castle Creek Biosciences
2 active drug programs in 2 registered trials: 2 Phase 3; Other; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| D-Fi Autologous fibroblasts genetically corrected with full-length COL7A1 gene encoding type VI | – | Phase 3 | Dystrophic Epidermolysis Bullosa | Sep 2027 |
| FCX-007 (dabocemagene autoficel) Autologous fibroblasts genetically corrected with COL7A1 gene encoding type VII collagen | – | Phase 3 | Recessive Dystrophic Epidermolysis Bullosa | Jul 2037 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06892639 | D-Fi | Phase 3 | Dystrophic Epidermolysis Bullosa | Other | Sep 2027 |
| NCT04213261 | FCX-007 (dabocemagene autoficel) | Phase 3 | Recessive Dystrophic Epidermolysis Bullosa | Other | Jul 2037 |
No annotated target.
–
CUTISS Gameto Merz Aesthetics DBV Technologies Merz North America
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.